PTC Therapeutics, Inc. (PTCT)Healthcare | Biotechnology | Warren, United States | NasdaqGS
81.33 USD
-3.52
(-4.148%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:17 a.m. EDT
PTC Therapeutics presents a stark contradiction between its price history and current business health. Over the last nine years, the stock has surged nearly 550 percent, trading well above its 200-day moving average and supported by a 'Buy' analyst consensus. However, the underlying fundamentals are deteriorating sharply, with revenue contracting by 76.8 percent and free cash flow remaining deeply negative while debt exceeds cash reserves. This disconnect suggests the market is betting on a turnaround, but the risk of continued cash burn is high. The lack of a dividend and high short interest further limit the appeal for income investors, making this a speculative hold rather than a core investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067052 |
| AutoETS | 0.068734 |
| AutoARIMA | 0.068734 |
| MSTL | 0.069200 |
| MSTL_66 | 0.086429 |
| MSTL_115 | 0.088895 |
| MSTL_66_115 | 0.109189 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.161 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 10.257 |
| Market Cap | 6,746,269,696 |
| Forward P/E | 26.35 |
| Beta | 0.53 |
| Profit Margins | -22.58% |
| Website | https://www.ptcbio.com |
As of July 11, 2026, 4:17 a.m. EDT: Speculators are positioning for long-term upside with heavy call open interest at the $70 strike for January 2027 expiration, significantly outweighing put open interest at that same strike. Near-term sentiment is mixed with elevated implied volatility and substantial put open interest at lower strikes for September 2026, suggesting hedging behavior alongside the bullish long-term bets.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.71552765 |
| Address1 | 500 Warren Corporate Center Drive |
| All Time High | 90.87 |
| All Time Low | 4.03 |
| Ask | 104.24 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 2,745,490 |
| Average Daily Volume3 Month | 1,816,934 |
| Average Volume | 1,816,934 |
| Average Volume10Days | 2,745,490 |
| Beta | 0.533 |
| Bid | 59.94 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | -2.177 |
| City | Warren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 81.33 |
| Current Ratio | 2.44 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 83.675 |
| Day Low | 80.69 |
| Display Name | PTC Therapeutics |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -20,901,000 |
| Ebitda Margins | -0.02527 |
| Enterprise To Ebitda | -362.477 |
| Enterprise To Revenue | 9.16 |
| Enterprise Value | 7,576,123,904 |
| Eps Current Year | 1.49 |
| Eps Forward | 3.08667 |
| Eps Trailing Twelve Months | -2.43 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 74.8464 |
| Fifty Day Average Change | 6.4836044 |
| Fifty Day Average Change Percent | 0.08662547 |
| Fifty Two Week Change Percent | 71.552765 |
| Fifty Two Week High | 90.87 |
| Fifty Two Week High Change | -9.540001 |
| Fifty Two Week High Change Percent | -0.10498515 |
| Fifty Two Week Low | 43.175 |
| Fifty Two Week Low Change | 38.155003 |
| Fifty Two Week Low Change Percent | 0.8837291 |
| Fifty Two Week Range | 43.175 - 90.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,371,735,000,000 |
| Float Shares | 73,173,759 |
| Forward Eps | 3.08667 |
| Forward P E | 26.348785 |
| Free Cashflow | -418,121,984 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 991 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.38324 |
| Gross Profits | 316,982,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0738 |
| Held Percent Institutions | 1.17587 |
| Implied Shares Outstanding | 82,949,338 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey. |
| Long Name | PTC Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 6,746,269,696 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1006484 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -186,727,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,038,251,329 |
| Number Of Analyst Opinions | 14 |
| Open | 83.242 |
| Operating Cashflow | -217,948,992 |
| Operating Margins | 0.16542 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 908 222 7000 |
| Pre Market Change | 0.08000183 |
| Pre Market Change Percent | 0.09836694 |
| Pre Market Price | 81.41 |
| Pre Market Time | 1,784,016,191 |
| Previous Close | 84.85 |
| Price Eps Current Year | 54.583893 |
| Price Hint | 2 |
| Price To Book | -37.35875 |
| Price To Sales Trailing12 Months | 8.156436 |
| Profit Margins | -0.22576 |
| Quick Ratio | 2.287 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.85714 |
| Region | US |
| Regular Market Change | -3.52 |
| Regular Market Change Percent | -4.14849 |
| Regular Market Day High | 83.675 |
| Regular Market Day Low | 80.69 |
| Regular Market Day Range | 80.69 - 83.675 |
| Regular Market Open | 83.242 |
| Regular Market Previous Close | 84.85 |
| Regular Market Price | 81.33 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 985,943 |
| Return On Assets | -0.015369999 |
| Revenue Growth | -0.768 |
| Revenue Per Share | 10.257 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 82,949,338 |
| Shares Percent Shares Out | 0.2087 |
| Shares Short | 17,315,032 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,674,185 |
| Short Name | PTC Therapeutics, Inc. |
| Short Percent Of Float | 0.2836 |
| Short Ratio | 7.34 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PTCT |
| Target High Price | 124.0 |
| Target Low Price | 65.0 |
| Target Mean Price | 94.14286 |
| Target Median Price | 92.5 |
| Total Cash | 1,892,462,976 |
| Total Cash Per Share | 22.815 |
| Total Debt | 2,722,317,056 |
| Total Revenue | 827,110,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 72.0451 |
| Two Hundred Day Average Change | 9.2849045 |
| Two Hundred Day Average Change Percent | 0.12887628 |
| Type Disp | Equity |
| Volume | 985,943 |
| Website | https://www.ptcbio.com |
| Zip | 7,059 |